Release Date: 21-Nov-2014
In the last decade, many significant technological advances have been made in the field of personalized cancer vaccine. In addition to the injections, implanted cancer vaccine technology has been use for better delivery and sustained release for longer periods. This is a novel research area, many biopolymers and cell binding methods have been developed for implants. At present, skin implant has been made for the therapeutic treatment of myeloma. It consists of a porous polymer which is made up of bio-degradable inert sutures and meshes, so body won’t be able to recognize and reject the implant.
Such cancer vaccine transplant consists of three different stimulants bonded on the inert matrix to activate the body’s immune system.
• First drug is granulocyte macrophage colony-stimulating factor (GM-CSF); it attracts the key immunity providing factors to enter in the implant. Dendritic cells are preferably attracted to the implant due to the presence of GM-CSF.
• Second, it consists of DNA that mimics viral and bacterial DNA. This DNA is non-pathogenic in nature, but it is found to be very effective in activating immune system. It sends a false signal of pathogen invasion; as a result, body prepares different immune cells to combat the breach in the defense mechanism.
• Third, patient’s biomarker for tumor cells is present in the implant. These unique biomarkers give a unique signal to dendritic cells, which in turns activates T-cells to search and destroy tumor cells.
In mice, such implants have shown to obliterate the myeloma. At present, these skin implants as cancer vaccines are at various phases of clinical trials for the assessment of their safety and efficacy.
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
For More Information Visit Report Weblink: “Global Cancer Vaccines Market & Pipeline Analysis”